P&G's beauty sales hurt by an unlikely headwind: A wastewater release in Japan

P&G's beauty sales hurt by an unlikely headwind: A wastewater release in Japan


Large advertisement of Japanese luxury skin care products brand, SK-II, in Causeway Bay, Hong Kong.

Miguel Candela | Lightrocket | Getty Images

Procter & Gamble on Tuesday said sales of its high-end SK-II skincare brand fell 34% in the Greater China region during its latest quarter — and it blamed an unlikely culprit.

With its high prices and reliance on travel retail, Japan-based SK-II has struggled as China’s economic recovery lags. But P&G executives also pointed to another factor that contributed to the brand’s cratering sales during the fiscal second quarter: anti-Japanese sentiment.

In August, Japan started releasing a huge amount of treated radioactive water from its Fukushima nuclear power plant, which was hit by a tsunami and earthquake more than a decade ago. The wastewater was dumped into the Pacific Ocean, leading to strong backlash from Japan’s neighbors — including China.

While Japan and the United Nations’ nuclear watchdog said the move was safe, China retaliated by banning all seafood imported from Japan. Chinese consumers followed with boycotts on Japanese brands, including P&G’s SK-II, fearing that their products would be tainted by radiation. P&G was among the companies that issued statements saying its products were safely produced as they tried to assuage consumer fears.

While the brand took a hit in the previous quarter, P&G executives said SK-II is already seeing sales turn around.

“Our consumer research indicates SK-II brand sentiment is improving, and we expect to see sequential improvement in the back half,” CFO Andre Schulten said on the company’s earnings conference call.

CEO Jon Moeller also reminded investors that previous tensions between Japan and China have hurt SK-II’s sales, but the brand always bounced back.

P&G’s overall beauty business reported flat volume for the quarter.

Shares of P&G rose 4% in morning trading on Tuesday after the company reported earnings that topped Wall Street’s estimates. Its quarterly sales, however, fell short of expectations.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More